Cardiff Oncology to Host Conference Call and Discuss First Quarter Financial Results and Clinical Programs
Cardiff Oncology, Inc. will be hosting a conference call on May 2nd at 4:30 p.m. ET/1:30 p.m. PT in San Diego to discuss their financial results for the first quarter ended March 31, 2024, which will be released after the close of trading on the same day. The company is a clinical-stage biotechnology company that utilizes PLK1 inhibition to develop novel therapies across various indications such as colorectal cancer, pancreatic cancer, small cell lung cancer, and triple negative breast cancer.
During the conference call, Cardiff Oncology will provide updates on their clinical programs and discuss their lead asset, onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care therapeutics to target tumor vulnerabilities and deliver superior clinical benefit. Individuals interested in listening to the live conference call can access it via the webcast link provided in the “Investors” section of the company’s website. A replay of the call will be available in the investor relations section following its completion. For more information about Cardiff Oncology and their clinical programs, visit their website at
For any inquiries regarding this event or for more information about Cardiff Oncology and their clinical programs, please contact James Levine at (858) 952-7670 or jlevine@cardiffoncology.com for financial matters or Kiki Patel from Gilmartin Group at (332) 895-3225 or email Kiki@gilmartinir.com for investor inquiries or Grace Spencer from Taft Communications at (609) 583-1151 or email grace@taftcommunications.com for media inquiries.
